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1. Introduction 
1.1. Pathophysiology of asthma and acute asthma exacerbations: Brief overview 
Asthma is a chronic respiratory disease that is prevalent worldwide. It is considered as a 
major cause of morbidity and a main contributor to the high health care expenditure 
especially in developed countries (Subbarao et al, 2009). There are two major pathological 
features in asthmatics’ airways, inflammation and hyperresponsiveness. These features are 
interrelated but not totally dependent on each other. Airway inflammatory changes include 
increased airway mucus secretions, airway wall edema, inflammatory cellular infiltrates, 
epithelial cell damage, smooth muscle hypertrophy, and submucosal fibrosis (Bergeron et al, 
2009).  The cellular infiltrates are mainly composed of eosinophils, neutrophils, mast cells, 
lymphocytes, basophils and macrophages. The ratio of these cells may widely vary between 
patients pointing to asthma heterogeneity (Holgate, 2008). Overall, asthma can be divided 
into eosinophilic, neutrophilic, and pauci-granulocytic phenotypes. The eosinophilic 
phenotype is characterized by predominant eosinophilic infiltration of the airways. Patients 
tend to be allergic, have asthma triggered by exposure to allergens and tend to respond well 
to glucocorticoids. The neutrophilic phenotype is characterized by predominant neutrophil 
infiltration of the airways. Patients tend to have severe, more aggressive, poorly controlled 
asthma, or acute asthma triggered by viral infection. They usually do not respond to 
glucocorticoids as good as the eosinophilic type. In the pauci-granulocytic phenotype 
neutrophils and eosinophils are almost absent (Holgate, 2008). 
Triggers of acute asthma exacerbation include allergens like pollens, animal dander, dust 
mites and mold; viral respiratory tract infections; irritants like smoke and dust; cold air and 
exercise. When pollens, for instance, are inhaled by an allergic individual, the allergenic 
protein is taken up by antigen presenting cells (dendritic cells) in the airway. It is then 
presented to naïve T-helper (Th) cells that develop into Th2 cell phenotype. These cells 
respond by secreting Th2 cytokines like IL-4 and IL-13 that cause allergen specific B-cells to 
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switch from IgM producing to IgE producing cells. These cytokines could also contribute to 
epithelial cell damage, increased mucus secretion and airway hyperresponsiveness. Th2 
cells also secrete IL-5 that stimulates eosinophil development, release from the bone marrow 
and their recruitment to the site of inflammation. IgE antibodies bind to their receptors on 
the surface of mast cells. Cross linking of adjacent IgE molecules leads to degranulation and 
release of mediators like histamine and tryptase that are key to features of immediate 
hypersensitivity reaction. Activation of mast cells and eosinophils will also stimulate the 
synthesis and release of lipid derived mediators like prostaglandins and cysteinyl 
leukotrienes that are very potent bronchoconstrictors. Moreover, activation of eosinophils 
leads to the release of mediators like eosinophil cataionic protein and major basic protein, 
which can cause airway epithelial cell damage and submucosal fibrosis. New evidence 
suggests that Th1 cells contribute to chronic changes in the airways including epithelial cells 
damage and smooth muscle cells activation. Regulatory T cells (Treg) inhibit Th2 cells by 
secreting IL-10 and tansforming growth factor  (TGF). Also, antigen specific Th17 cells 
were found to play an important role in neutrophilic airway inflammation and the process 
of airway remodeling (fixed changes to the airway) through the secretion of IL-17A and IL-
17F (figure 1). This is a very quick overview, but many other changes take place during this 
process that are beyond the scope of this chapter. 
 
Figure 1. Major immunopahtologic processes that take place in the bronchial airways of patients with 
asthma. Please see the text for detailed description.  FcRI, high-affinity receptor for IgE; IFN, 
interferon-; TCR, T-cell receptor; TNF, tumour-necrosis factor. Reprinted by permission from 
Macmillan Publishers Ltd: Nature Reviews Immunology. Stephen T. Holgate and Riccardo Polosa. 
Treatment strategies for allergy and asthma. Vol. 8(3):Page 220, Copyright 2008. 
